INmune Bio, Inc. (INMB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
INmune Bio, Inc. (INMB) trades at $1.67 with AI Score 28/100 (Grade F). INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the innate immune system. Market cap: $44.26M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for INMB: INMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INMB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INMB: 1/1 perspectives are bearish.
How is this calculated? →INmune Bio, Inc. (INMB) Healthcare & Pipeline Overview
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that target the innate immune system to treat cancers and chronic inflammatory diseases. Their pipeline includes INKmune, INB03, and XPro1595, each designed to address unmet needs in oncology and neuroinflammation, positioning them in a competitive biotech landscape.
What Is the Investment Thesis for INMB?
INmune Bio, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on reprogramming the innate immune system offers a novel approach to treating cancers and chronic inflammatory diseases. Key value drivers include the successful advancement of its clinical programs, particularly INKmune, INB03, and XPro1595, through clinical trials and regulatory approval. Positive clinical data readouts could serve as significant catalysts, driving investor interest and potentially leading to strategic partnerships or acquisitions. However, the company faces significant risks associated with clinical development, regulatory hurdles, and funding requirements. Failure to demonstrate efficacy or safety in clinical trials could negatively impact the company's valuation. As of 2026, the company's market capitalization is $0.04 billion, reflecting the inherent uncertainty associated with clinical-stage biotech companies. The company's success hinges on its ability to navigate these challenges and successfully commercialize its innovative immunotherapies.
Based on FMP financials and quantitative analysis
INMB Key Highlights
- INmune Bio is a clinical-stage immunotherapy company focused on reprogramming the innate immune system.
- The company's lead programs include INKmune for ovarian carcinoma and myelodysplastic syndrome, INB03 for hematologic malignancies and solid tumors, and XPro1595 for Alzheimer's disease.
- Strategic license agreements with Xencor, Inc., Immune Ventures, LLC, University of Pittsburgh, and University College London support the company's research and development efforts.
- The company is headquartered in Boca Raton, Florida, and has a market capitalization of $44.26M as of May 10, 2026.
- INmune Bio is actively involved in clinical trials to evaluate the safety and efficacy of its product candidates.
Who Are INMB's Competitors?
INMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| XNCR Xencor, Inc. | $15.00 | +0.02% | $1.11B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INMB's Key Strengths?
- Novel approach to immunotherapy targeting the innate immune system.
- Diverse pipeline of product candidates.
- Strategic license agreements with leading institutions.
- Experienced management team.
What Are INMB's Weaknesses?
- Clinical-stage company with no approved products.
- High reliance on clinical trial success.
- Limited financial resources.
- Small number of employees.
What Could Drive INMB Stock Higher?
- Clinical trial data readouts for INKmune in relapse refractory ovarian carcinoma.
- Clinical trial data readouts for INB03 in hematologic malignancies and solid tumors.
- Clinical trial data readouts for XPro1595 in Alzheimer's disease.
- Advancement of product candidates through clinical development.
- Potential for strategic partnerships and collaborations.
What Are the Key Risks for INMB?
- Financial-distress signal — its Altman Z-Score of -9.66 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from larger pharmaceutical companies.
- Difficulty in raising capital.
- Dependence on key personnel.
What Are the Growth Opportunities for INMB?
- Expansion of INKmune into New Indications: INKmune, currently in development for relapse refractory ovarian carcinoma and high-risk myelodysplastic syndrome (MDS), has the potential to be expanded into other hematologic malignancies. The market for MDS treatment alone is projected to reach $3 billion by 2028. Successful clinical trials in additional indications could significantly broaden INKmune's market reach and revenue potential, providing a substantial growth opportunity for INmune Bio.
- Advancement of INB03 in Solid Tumors: INB03, an immunotherapy targeting hematologic malignancies and solid tumors, represents a significant growth opportunity for INmune Bio. The global market for solid tumor therapies is estimated to reach $200 billion by 2027. Positive clinical trial results demonstrating INB03's efficacy in treating specific solid tumors could lead to regulatory approval and commercialization, driving substantial revenue growth for the company.
- Development of XPro1595 for Alzheimer's Disease: XPro1595, INmune Bio's program for the treatment of Alzheimer's disease, targets neuroinflammation, a key driver of the disease. The Alzheimer's disease market is projected to reach $12 billion by 2028. Successful clinical trials demonstrating XPro1595's ability to slow or reverse cognitive decline could position INmune Bio as a leader in the Alzheimer's disease treatment space, creating a significant growth opportunity.
- Strategic Partnerships and Collaborations: INmune Bio can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources, enabling the company to expand its pipeline and reach a wider patient population. Successful collaborations could significantly enhance INmune Bio's growth prospects.
- Expansion into New Geographic Markets: INmune Bio has the opportunity to expand its operations into new geographic markets, particularly in Europe and Asia. These markets offer significant growth potential due to their large patient populations and increasing healthcare spending. Establishing a presence in these markets could drive revenue growth and diversify the company's revenue streams. The timeline for this expansion would depend on regulatory approvals and market access strategies.
What Opportunities Does INMB Have?
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Positive clinical trial results.
- Growing market for immunotherapies.
What Threats Does INMB Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Difficulty in raising capital.
What Are INMB's Competitive Advantages?
- Proprietary immunotherapy technologies.
- Strong intellectual property portfolio.
- Strategic license agreements with leading institutions.
- Focus on reprogramming the innate immune system.
What Does INMB Do?
INmune Bio, Inc., incorporated in 2015 and headquartered in Boca Raton, Florida, is a clinical-stage immunotherapy company dedicated to developing novel therapies that reprogram the patient's innate immune system to combat disease. The company's core focus is on creating and commercializing product candidates aimed at treating hematologic malignancies, solid tumors, and chronic inflammation. INmune Bio's approach centers on harnessing the power of the innate immune system, the body's first line of defense, to fight diseases that have proven difficult to treat with conventional methods. The company's development programs include INKmune, an immunotherapy designed to treat women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome (MDS). INB03 is another key program, targeting patients with hematologic malignancies and solid tumors. XPro1595, a third program, is focused on the treatment of Alzheimer's disease by targeting neuroinflammation. These programs represent INmune Bio's commitment to addressing significant unmet medical needs in oncology and neurodegenerative diseases. INmune Bio has established strategic license agreements with various institutions and companies, including Xencor, Inc., Immune Ventures, LLC, University of Pittsburgh, and University College London. These collaborations provide access to key technologies and intellectual property, strengthening the company's development pipeline and capabilities. As a clinical-stage company, INmune Bio is actively involved in conducting clinical trials to evaluate the safety and efficacy of its product candidates, with the goal of bringing innovative immunotherapies to market.
What Products and Services Does INMB Offer?
- Develop immunotherapies to reprogram the innate immune system.
- Create product candidates for treating hematologic malignancies.
- Develop treatments for solid tumors.
- Focus on therapies for chronic inflammation.
- Develop INKmune for relapse refractory ovarian carcinoma and myelodysplastic syndrome.
- Develop INB03 for hematologic malignancies and solid tumors.
- Develop XPro1595 for Alzheimer's disease.
How Does INMB Make Money?
- Develop and commercialize immunotherapeutic drugs.
- License intellectual property and technologies.
- Conduct clinical trials to evaluate drug safety and efficacy.
- Seek regulatory approval for product candidates.
What Industry Does INMB Operate In?
INmune Bio operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in genomics, proteomics, and immunotherapy. INmune Bio's focus on reprogramming the innate immune system positions it within the innovative segment of immunotherapy, which is gaining increasing attention for its potential to treat a wide range of diseases. The company competes with both large pharmaceutical companies and smaller biotech firms that are developing similar immunotherapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.
Who Are INMB's Key Customers?
- Patients with hematologic malignancies.
- Patients with solid tumors.
- Patients with chronic inflammation.
- Patients with Alzheimer's disease.
Company Profile
INmune Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO David J. Moss. INMB has traded publicly since 2019.
How INmune Bio, Inc. Is Valued
INmune Bio, Inc. carries a market capitalization of $44.26M, placing it in the micro-cap category. Relative to its peer group, INMB's quantitative score of 28/100 is below the peer average of 78/100.
Key Financial Metrics
Its free cash flow yield is -47.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -96.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
INmune Bio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.66 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project INmune Bio, Inc. revenue of about $133K for fiscal 2026, with EPS near $-0.70. The estimate reflects 4 contributing analysts.
INMB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in INmune Bio's future prospects, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively as discussions around INmune's innovative therapies gain traction, reflecting growing interest.
- The company's focus on immune modulation aligns well with current healthcare trends, positioning it favorably in a competitive market.
- Recent clinical trial updates have sparked optimism among investors, as positive results could enhance the company's credibility and market standing.
Bear Case
- Market perception remains cautious due to the high-risk nature of biotech investments, with many investors wary of potential setbacks.
- Some community members express concerns over the lengthy timelines associated with drug development, which could delay profitability.
- Recent fluctuations in sentiment indicate a divided opinion, with bearish voices questioning the sustainability of the current momentum.
- Regulatory hurdles in the biotech sector continue to loom large, creating uncertainty about the approval process for INmune's therapies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
INMB Latest News
-
Earnings Scheduled For October 30, 2025
benzinga · Oct 30, 2025
-
Earnings Scheduled For May 8, 2025
benzinga · May 8, 2025
INMB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INMB.
Price Targets
Wall Street price target analysis for INMB.
INMB MoonshotScore
What does this score mean?
The MoonshotScore rates INMB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David J. Moss
CEO
David J. Moss serves as the CEO of INmune Bio, Inc., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies, where he focused on strategic planning, business development, and clinical operations. Moss has a proven track record of driving innovation and growth in the healthcare sector. He is responsible for managing the company's overall strategy and operations, overseeing clinical development programs, and fostering collaborations with key partners.
Track Record: Under David J. Moss's leadership, INmune Bio has advanced its pipeline of immunotherapies, including INKmune, INB03, and XPro1595, through clinical trials. He has successfully secured strategic license agreements with institutions such as Xencor, Inc. and the University of Pittsburgh. Moss has also focused on building a strong team and fostering a culture of innovation within the company. His leadership is crucial to INmune Bio's efforts to develop and commercialize novel therapies for cancer and chronic inflammatory diseases.
INMB Healthcare Stock FAQ
What does INmune Bio, Inc. do?
INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs that reprogram the patient's innate immune system to treat diseases. The company develops and commercializes product candidates for hematologic malignancies, solid tumors, and chronic inflammation. Their lead programs include INKmune, which targets relapse refractory ovarian carcinoma and high-risk myelodysplastic syndrome; INB03, an immunotherapy for hematologic malignancies and solid tumors; and XPro1595, a treatment for Alzheimer's disease. INmune Bio's innovative approach focuses on harnessing the power of the innate immune system to fight diseases that have proven difficult to treat with conventional methods.
What do analysts say about INMB stock?
As of May 10, 2026, analyst coverage of INMB stock is limited due to its small market capitalization and clinical-stage nature. Key valuation metrics are highly dependent on the successful advancement of its clinical programs. Investors should closely monitor clinical trial results and regulatory milestones. The company's growth potential is tied to its ability to demonstrate efficacy and safety in clinical trials and secure regulatory approvals. Analyst consensus is not readily available, reflecting the uncertainty associated with clinical-stage biotech companies. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in INMB.
What are the main risks for INMB?
The main risks for INMB include clinical trial failures, regulatory hurdles, competition from larger pharmaceutical companies, and difficulty in raising capital. As a clinical-stage company, INMB is highly dependent on the successful advancement of its product candidates through clinical trials. Failure to demonstrate efficacy or safety in clinical trials could negatively impact the company's valuation. The company also faces regulatory risks associated with obtaining approval from regulatory agencies such as the FDA. Competition from larger pharmaceutical companies with greater resources and established market presence poses a significant threat. INMB may also face challenges in raising capital to fund its research and development activities.
What are the key growth opportunities for INMB in healthcare?
INmune Bio, Inc. has several key growth opportunities within the healthcare sector. These include expanding the indications for its existing pipeline drugs, such as INKmune, into other cancer types. Another opportunity lies in securing strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its products. Furthermore, INmune Bio can capitalize on the growing market for immunotherapies by developing innovative treatments for chronic inflammatory diseases and neurodegenerative disorders like Alzheimer's disease. Successful clinical trial outcomes and regulatory approvals will be critical to realizing these growth opportunities.
How does INmune Bio, Inc. navigate regulatory approval processes?
INmune Bio, Inc. navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA in the United States. The company conducts rigorous preclinical and clinical trials to demonstrate the safety and efficacy of its product candidates. INmune Bio maintains detailed documentation of its research and development activities and works closely with regulatory experts to ensure compliance with all applicable regulations. The company's regulatory strategy involves submitting comprehensive regulatory filings, such as Investigational New Drug (IND) applications and New Drug Applications (NDAs), and actively engaging with regulatory agencies to address any questions or concerns. The success of INmune Bio's regulatory efforts depends on the quality of its clinical data and its ability to demonstrate a favorable benefit-risk profile for its products.
What are the key factors to evaluate for INMB?
INmune Bio, Inc. (INMB) holds an AI score of 28/100 (low). Not financial advice.
How frequently does INMB data refresh on this page?
INMB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INMB's recent stock price performance?
INmune Bio, Inc. (INMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach to immunotherapy targeting the innate immune system. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.